A new study from British scientists suggests that long-term, low-dose aspirin use may modestly decrease the risk of dying of certain cancers, though experts warn the study isn't strong enough to advise healthy people start taking a pill that can cause bleeding and other problems. In a new observational analysis published online Tuesday in the medical journal Lancet, Peter Rothwell of the University of Oxford and colleagues looked at eight studies that incorporated more than 30,000 patients and cut the hazard of death from certain cancers by 20 percentage?
While some experts said the study adds to evidence of aspirin's potential to cut cancer risk, others said it falls short of changing advice to healthy people, and it failed to show the profit apply equally to women. The study typically compared men who took a daily dose of at least 75 milligrams of aspirin for heart problems. On average, the studies lasted at least four years. Researchers used national cancer registries to get information on participants after the studies ended, though they weren't sure how many aspirin takers sustained using it or how many people in the comparison groups may have started.
0 comments:
Post a Comment